Therapies for dopaminergic‐induced dyskinesias in parkinson disease
Identifieur interne : 000114 ( Main/Exploration ); précédent : 000113; suivant : 000115Therapies for dopaminergic‐induced dyskinesias in parkinson disease
Auteurs : Mildred D. Gottwald [États-Unis] ; Michael J. Aminoff [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2011-06.
Abstract
Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927
Url:
DOI: 10.1002/ana.22423
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><author><name sortKey="Gottwald, Mildred D" sort="Gottwald, Mildred D" uniqKey="Gottwald M" first="Mildred D." last="Gottwald">Mildred D. Gottwald</name></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/ana.22423</idno><idno type="url">https://api.istex.fr/document/0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000119</idno><idno type="wicri:Area/Main/Curation">000098</idno><idno type="wicri:Area/Main/Exploration">000114</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><author><name sortKey="Gottwald, Mildred D" sort="Gottwald, Mildred D" uniqKey="Gottwald M" first="Mildred D." last="Gottwald">Mildred D. Gottwald</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Neurology, University of California, San Francisco, San Francisco</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">69</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="919">919</biblScope><biblScope unit="page" to="927">927</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</idno><idno type="DOI">10.1002/ana.22423</idno><idno type="ArticleID">ANA22423</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Gottwald, Mildred D" sort="Gottwald, Mildred D" uniqKey="Gottwald M" first="Mildred D." last="Gottwald">Mildred D. Gottwald</name></region><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000114 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000114 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9
|texte= Therapies for dopaminergic‐induced dyskinesias in parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |